ABBV-744 CANCER TREATMENT CLINICAL TRIALS - AN OVERVIEW

The existing work examined the potential of using ARV-825 and ABBV-744 to improve the effectiveness of tamoxifen or fulvestrant furthermore palbociclib. ARV-825 was effective in equally p53 wild-type (WT) breast tumor cells and in cells lacking functional p53 either on your own or in combination with tamoxifen, whilst the effectiveness of ABBV-744